HC Wainwright Reaffirms Buy Rating for Oruka Therapeutics (NASDAQ:ORKA)

Oruka Therapeutics (NASDAQ:ORKA)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a research report issued to clients and investors on Thursday, Marketbeat Ratings reports. They currently have a $120.00 target price on the stock. HC Wainwright’s price objective would indicate a potential upside of 41.50% from the company’s current price.

ORKA has been the subject of a number of other reports. UBS Group boosted their price target on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the company a “buy” rating in a research report on Wednesday, July 1st. Mizuho set a $120.00 target price on shares of Oruka Therapeutics in a research report on Thursday, September 3rd. Weiss Ratings upgraded shares of Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 15th. Guggenheim restated a “buy” rating and set a $200.00 price target on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. Finally, Piper Sandler restated an “overweight” rating and set a $180.00 price target on shares of Oruka Therapeutics in a research report on Tuesday, June 2nd. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $128.91.

Oruka Therapeutics Price Performance

Shares of NASDAQ:ORKA traded down $0.68 during trading on Thursday, hitting $84.81. 131,101 shares of the company were exchanged, compared to its average volume of 1,098,617. Oruka Therapeutics has a 52-week low of $15.00 and a 52-week high of $115.51. The stock has a 50 day moving average of $96.83 and a 200 day moving average of $75.69. The company has a market cap of $5.62 billion, a PE ratio of -41.78 and a beta of -0.34.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.04). Sell-side analysts forecast that Oruka Therapeutics will post -2.42 EPS for the current fiscal year.

Insider Activity

In related news, SVP Arjun Agarwal sold 10,000 shares of the stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $106.66, for a total value of $1,066,600.00. Following the completion of the transaction, the senior vice president directly owned 15,312 shares of the company’s stock, valued at $1,633,177.92. This represents a 39.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Joana Goncalves sold 7,947 shares of the stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $92.38, for a total transaction of $734,143.86. Following the completion of the transaction, the insider directly owned 31,771 shares of the company’s stock, valued at approximately $2,935,004.98. The trade was a 20.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 122,950 shares of company stock valued at $11,528,806. Insiders own 23.49% of the company’s stock.

Hedge Funds Weigh In On Oruka Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in shares of Oruka Therapeutics during the 2nd quarter worth approximately $474,916,000. Jupiter Topco LLC purchased a new stake in Oruka Therapeutics in the second quarter worth $130,968,000. Bank of America Corp DE bought a new stake in shares of Oruka Therapeutics during the second quarter worth $33,578,000. Braidwell LP purchased a new stake in shares of Oruka Therapeutics during the second quarter valued at $26,473,000. Finally, Atika Capital Management LLC purchased a new stake in shares of Oruka Therapeutics during the first quarter valued at $11,277,000. 56.44% of the stock is currently owned by hedge funds and other institutional investors.

Key Oruka Therapeutics News

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: Encouraging ORKA-001 psoriasis data: Results from the Phase 2a EVERLAST-A trial showed that psoriasis responses deepened through week 28, supporting the durability and potential competitive profile of ORKA-001. Oruka Announces Positive Week 28 Results
• Positive Sentiment: Analyst support remains strong: Wedbush reaffirmed its “Outperform” rating with a $165 price target, while HC Wainwright maintained a “Buy” rating and a $120 target. UBS also said ORKA-001 retains a competitive profile following the clinical update. Wedbush Rating and Price Target
• Positive Sentiment: Pipeline expansion: Oruka provided an update on its ongoing randomized, placebo-controlled study of ORKA-002 in hidradenitis suppurativa, giving investors an additional potential clinical catalyst beyond psoriasis. ORKA-002 Trial Progress
• Neutral Sentiment: Short-interest data appears inconclusive: A report described a sharp increase in short interest, but also listed total short interest at zero shares and a zero-day short-interest ratio, making the figures difficult to interpret as a meaningful trading signal.
• Negative Sentiment: Safety disclosures overshadowed efficacy: Although ORKA-001 delivered deeper psoriasis clearance at week 28, safety information appears to have prompted investor caution. Reports noted that the stock fell even as the efficacy results improved, suggesting expectations were already high and the market wants greater clarity on the treatment’s risk-benefit profile. ORKA Stock and Week 28 Data

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc (NASDAQ:ORKA) is a clinical-stage biotechnology company developing long-acting monoclonal antibody therapies for immune-mediated diseases. The company’s research is focused on creating medicines that may allow less frequent dosing than existing biologic treatments.

Oruka’s initial development programs are aimed at inflammatory conditions, including psoriasis. Its pipeline includes engineered antibody candidates designed to target important immune pathways, including interleukin-23 and interleukin-17.